KCTD5 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from HeLa cervical adenocarcinoma cells, designed for loss-of-function studies of KCTD5. This polyclonal knockout model preserves population-level heterogeneity, enabling investigation of KCTD5-dependent pathways without the need for clonal isolation. Generated via CRISPR/Cas9-mediated gene disruption, these cells serve as a versatile tool for studying protein homeostasis and signal transduction.
The HeLa cell line is an immortalized epithelial model derived from a cervical adenocarcinoma, widely employed in cancer research. Its robust proliferation and ease of genetic manipulation facilitate dissection of complex signaling cascades, including those involving ubiquitin ligase adaptors. HeLa’s well-characterized background supports reliable integration of gene-edited populations for mechanistic studies.
KCTD5 acts as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase, mediating polyubiquitination and proteasomal degradation of G protein ?¦? subunits (GNB1/GNG2). This function directly regulates GPCR signaling, particularly via the GABA-B receptor (GABBR1/GABBR2). KCTD5 also contributes to protein quality control and ER-associated degradation, linking the unfolded protein response (UPR) to clearance of misfolded proteins. Through these interactions, KCTD5 integrates stress signals with receptor-mediated signal transduction, influencing cellular proteostasis and adaptive responses.
In HeLa cancer cells, KCTD5 knockout provides a platform to explore its role in proteasomal degradation and GPCR signaling, both commonly dysregulated in malignancy. KCTD5 has been associated with neurological disorders such as schizophrenia, highlighting its relevance across disease areas. Disruption of KCTD5 in this proliferative background may uncover dependencies on protein quality control mechanisms or altered signaling networks that contribute to tumorigenesis. The polyclonal nature avoids clonal bias, enabling studies of response heterogeneity.
Applications include ubiquitin-proteasome pathway analysis, GPCR signaling assays (cAMP, calcium flux), and proteasome activity profiling. Co-immunoprecipitation can assess interactions with CUL3, RBX1, or G protein subunits in a KCTD5-null context. Standard techniques such as Western blotting, RT-qPCR, and immunofluorescence validate target protein changes. Population-based assays like flow cytometry and cell proliferation/apoptosis studies are well-suited. Gene editing can be confirmed using T7E1 or Surveyor nuclease assays. Please contact Ascent Research for additional details.
